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Abstract: The value of cross-sectional liver imaging is evaluated by the accuracy, sensitivity, 
and specificity of the specific imaging technique. Magnetic resonance imaging (MRI) has become 
a key technique for the characterization and detection of focal and diffuse liver disease. More 
recently, gadoxetic acid, the hepatocyte-specific MR contrast agent, was clinically approved and 
introduced in many countries. Gadoxetic acid may be considered a “molecular imaging” probe 
because the compound is actively taken into hepatocytes via the ATP-dependent organic anion 
transport system in the plasma membrane for the hepatic uptake. The transport of gadoxetic 
acid from the cytoplasm to the bile is mainly determined by the capacity of the transport protein 
glutathione-S-transferase. Gadoxetic acid enhances hepatocyte-containing lesions and improves 
detection of lesions devoid of normal hepatocytes, such as metastases. Innovative rapid MR 
acquisition techniques with near isotropic 3D pulse sequences with fat saturation parallel the 
technical progress made by multidetector computed tomography combined with an impressive 
improvement in tumor–liver contrast when used for gadoxetic acid-enhanced MRI. The purpose 
of this review is to provide an overview of the development, clinical testing, and applications 
of this novel MR contrast agent.
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Introduction
The clinical need for liver imaging with high accuracy, sensitivity, and specificity is 
a constant struggle for better imaging techniques. Gadoxetic acid may be considered 
a “molecular imaging” probe because the compound is actively taken into hepato-
cytes via ATP-dependent surface receptors. Magnetic resonance imaging (MRI) has 
become a key technique for the characterization and detection of focal liver disease 
with the use of gadoxetic acid, currently the most sophisticated cell-specific contrast 
agent developed for hepatic MRI. The compound enhances hepatocyte-containing 
lesions and improves the detection of lesions devoid of normal hepatocytes, such as 
metastases (Figure 1). Technical improvements of T1-weighted MRI techniques and 
fat-saturated 3D techniques that provide computed tomography (CT)-like impressions 
of anatomy further improve clinical acceptance.
The purpose of this review is to provide an overview of the development, clinical 
testing, and applications (Figures 1–5) of this novel MR contrast agent.
Clinical background on liver tumors
The prognosis of malignant liver tumors is, in general, poor. However, for example, 
25% of patients with liver metastases from colorectal cancer may be surgical   candidates, Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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with a 5-year survival of up to 40%. The therapeutic 
  armamentarium is growing significantly with the increase 
in the survival time of primary and secondary malignant 
liver tumors.1–3
Hepatocellular carcinoma (HCC) is the third leading 
cause of cancer mortality worldwide (Figures 3 and 4). Most 
of the HCCs that are associated with hepatitis B virus (HBV) 
occur in patients who have hepatitis B infection during most 
of their lives, also called chronic hepatitis B. The develop-
ment of HCC is also associated with chronic hepatitis C 
virus (HCV). Most of the patients who develop HCC as a 
result of HCV will have liver cirrhosis. The average time to 
develop HCC after initial exposure to HCV is about 28 years 
and usually about 8–10 years after the development of liver 
cirrhosis. The way in which HCV causes HCC is not well 
understood.4
Cirrhosis caused by chronic alcohol consumption is the 
most common association of HCC in the developed world. 
Actually, we now understand that many of these cases are 
also infected with chronic HCV . The usual observation is an 
individual with alcoholic cirrhosis who has stopped drinking 
for 10 years develops HCC. It is somewhat unusual for an 
actively drinking alcoholic to develop HCC. When drink-
ing is stopped, the liver cells try to heal by regenerating 
(reproducing). During this active regeneration, a cancer-
producing genetic change (mutation) can occur, which 
explains the occurrence of HCC even after drinking has 
been stopped.5–7 Aflatoxin B1 is the most potent liver cancer-
causing chemical known and has been implicated in the 
development of HCC in Southern China and Sub-Saharan 
Africa.8
Individuals with most types of cirrhosis of the liver 
are at an increased risk of developing HCC. In addi-
tion to the conditions described earlier (hepatitis B, 
hepatitis C, alcoholic cirrhosis, and hemochromatosis), 
α1-antitrypsin deficiency, a hereditary condition that 
can cause   emphysema and   cirrhosis, may lead to HCC. 
Liver cancer is also strongly associated with hereditary 
tyrosinemia, a childhood biochemical abnormality that 
results in early cirrhosis. Certain causes of cirrhosis are 
less frequently associated with HCC than are other causes. 
For example, HCC is rarely seen with the cirrhosis in Wil-
son’s disease (abnormal copper metabolism) or primary 
sclerosing cholangitis (chronic scarring and narrowing 
of the bile ducts). HCC was earlier thought to be rarely 
found in primary biliary cirrhosis (PBC) as well. Recent 
studies, however, show that the frequency of HCC in PBC 
is comparable to that in other forms of cirrhosis.9
Figure 1 Metastases. Plain T1-weighted spoiled 2D gradient echo (GRe) A) T2-weighted half-Fourier acquisition single-shot turbo spin-echo (HASTe) B) hepatocellular phase 
gadoxetic acid-enhanced fat-suppressed (FS) T1-weighted spoiled 3D GRe C) and diffusion-weighted imaging (Dwi) D) in the axial plane. Multiple liver metastases are better 
visualized on gadoxetic acid-enhanced magnetic resonance imaging (MRi) and also Dwi compared to plain T1- and T2-weighted MRi.Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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Figure 2 Focal nodular hyperplasia (FNH). Plain T1-weighted spoiled 2D gradient echo (GRe) A) T2-weighted half-Fourier acquisition single-shot turbo spin-echo (HASTe)   
B) arterial-phase gadoxetic acid-enhanced fat-suppressed (FS) T1-weighted spoiled 3D GRe C) portal venous-phase gadoxetic acid-enhanced FS T1-weighted spoiled 3D 
GRe D) hepatocellular phase in the axial E) and coronal plane F) gadoxetic acid-enhanced FS T1-weighted spoiled 3D GRe 20 min following contrast injection. The liver 
demonstrates a lesion in the right liver lobe, which is slightly hypointense compared with liver on T1-weighted A) and hyperintense compared on T2-weighted imaging B). The 
tumor enhances on dynamic images (C and D) and signal intensity stays high on late phase images due to hepatocellular uptake (E and F) characterizing the lesion as FNH.
E F
The prognosis of HCC is determined by the anatomic 
extent of tumor (stage), such as the size of the biggest 
lesion, number of lesions, lobar vs bilobar involvement, 
vascular invasion, and metastasis.10 There are other factors 
that are equally important: the grade or aggressiveness of 
the tumor. In addition to pathology, very high α-fetoprotein 
is often indicative of tumors that are very aggressive. More 
recently, there has been very exciting work done with gene 
array technology to analyze the mutation rate of tumors. 
In HCC prognosis, the severity of cirrhosis is another very 
important factor, as is the functional status of the patient. 
Finally, the treatment administered is also important. The 
staging system needs to be appropriate for the treatments 
used.11,12
Benign liver tumors are relatively common.13 Most are 
asymptomatic and are detected incidentally on ultrasonog-
raphy, CT, or MRI. The three most common types of benign 
liver tumors are hemangioma, focal nodular hyperplasia 
(FNH), and hepatocellular adenoma. Hemangioma is a mass 
of abnormal blood vessels. Up to 5% of adults have small 
asymptomatic liver hemangiomas, which do not require any 
treatment. Sometimes, infants with large liver hemangiomas 
require surgery to prevent clotting. FNH is characterized by 
a stellate central scar and hyperplastic nodules (Figure 2). Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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Although some large FNHs may be associated with   significant 
symptoms, more frequently, they are discovered incidentally 
by physical examination or by the development of unrelated 
symptoms.14 Hepatocellular adenoma occurs most often in 
women of childbearing age. Most of these tumors remain 
undetected. Sometimes, an adenoma will rupture and bleed 
into the abdominal cavity, requiring surgery. Adenomas rarely 
become cancerous.15
In the Institute for Pathology of the University of 
Cologne, 12,161 liver tissue cases are registered. Of them, 
1,357 cases (11.2%) showed tumors or tumor-like masses. 
Liver metastases of solid tumors were the largest group with 
611 cases (5.0%). Adenocarcinomas were the largest group 
of metastases with 400 cases (65.5%); 48.2% of this group 
had metastases of colorectal cancer; 13.5%, pancreatic cancer; 
13%, breast cancer; 6.2%, gastric cancer; 4.5%, lung cancer; 
and 3.7%, esophageal cancer.16
The radiological diagnosis of liver metastasis involves 
detection, characterization, and tumor staging. Knowledge 
of the histopathologic changes that occur with metastases 
provides the best approach to the accurate interpretation of 
radiological imaging findings, and in particular, radiologists 
need to choose the appropriate imaging methods based on 
such knowledge. As most of the metastases are hypovascu-
lar, the merits of the routine acquisition of hepatic arterial 
  dominant-phase images by contrast-enhanced MRI (CE-MRI) 
are disputable. Hepatic arterial dominant-phase images may 
be obtained when hypervascular tumors are suspected. 
Figure 3 well-differentiated hepatocellular carcinoma (HCC). Plain T1-weighted spoiled 2D gradient echo (GRe) A) T2-weighted half-Fourier acquisition single-shot turbo 
spin-echo (HASTe) B) hepatocellular phase gadoxetic acid-enhanced fat-suppressed (FS) T1-weighted spoiled 3D GRe C) and gross pathology D) in the axial plane. A small 
liver mass in S4b is faintly visible on unenhanced sequences showing characteristics of a HCC nodule such as a rim on T1-weighted magnetic resonance imaging (MRi) (A). 
Gadoxetic acid-enhanced MRI shows an enhancing lesion mimicking a benign lesion based on uptake into the well-differentiated HCC confirmed at surgery. Gross pathology 
is courtesy of Prof Thomas Rüdiger.
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Figure 4 Anaplastic hepatocellular carcinoma (HCC) following radioembolization. Plain T1-weighted spoiled 2D gradient echo (GRe) A) T2-weighted half-Fourier acquisition 
single-shot turbo spin-echo (HASTe) B) diffusion-weighted imaging (Dwi) C) and hepatocellular phase gadoxetic acid-enhanced fat-suppressed (FS) T1-weighted spoiled 
3D GRe D) in the axial plane. The large hypointense zone in segment 8 resembles an area following radioembolization of the previously more circumscribed tumor. Multiple 
new satellite tumors can only be appreciated on gadoxetic acid-enhanced MRi.
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  Imaging during the portal venous phase is essential for detect-
ing metastases, evaluating intrahepatic vessel invasion, and 
assessing intratumoral necrosis or fibrosis. Equilibrium- to 
delayed-phase imaging performed 3–5 minutes after the 
administration of contrast agent may improve the detection 
of intratumoral fibrosis and may   occasionally lead to more 
accurate tissue characterization. MRI offers diagnostic 
information on vascularity, amount of free water, hemor-
rhage, fibrosis, necrosis, and water molecule diffusion in 
metastases.17
Rationale for gadoxetic  
acid-enhanced MRI
Gadoxetic acid was developed to improve the detection 
and characterization of focal liver disease (Figures 1–5) 
compared with nonspecific low–molecular weight gado-
linium chelates.18–21 At the time of development, dynamic 
T1-weighted MRI was not able to cover the entire liver 
during bolus injection of nonspecific low-molecular weight 
gadolinium chelates comparable to CT. Therefore, it was 
hypothesized that an agent that may stay in the liver for some 
time may allow for better imaging at a higher resolution.22 
The gadopentetate dimeglumine molecule serves as the 
backbone with an added lipophilic side chain binding to the 
surface receptors on the hepatocytes. Up to 50% of the agent 
is subsequently taken up into hepatocytes and later released 
into the bile.18 Agents with these characteristics are called 
hepatocyte-specific or hepatobiliary contrast agents, which 
have a hepatocellular phase during which the contrast agent 
is concentrated in hepatocytes before being released into the 
bile. This phase may last for several hours, and the contrast 
agent in the hepatocytes shortens T1-relaxation time, thus 
significantly increasing the signal on T1-weighted images. 
It has been shown that gadoxetic acid enters plasma mem-Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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Figure 5 Cholangiocellular carcinoma. Plain T1-weighted spoiled 2D gradient echo (GRe) A) T2-weighted half-Fourier acquisition single-shot turbo spin-echo (HASTe) B) 
hepatocellular phase gadoxetic acid-enhanced fat-suppressed (FS) T1-weighted spoiled 3D GRe C) and diffusion-weighted imaging (Dwi) D) in the axial plane. A large central 
liver mass is demonstrated on unenhanced sequences. Gadoxetic acid-enhanced magnetic resonance imaging (MRi) shows the lesion much better and additional satellite 
lesions in both liver lobes with increased conspicuity.
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brane vesicles following a linear, concentration-dependent 
mechanism up to 1.5 mM of substrate. Sulfobromophthalein 
and taurocholate, but not unconjugated bilirubin, inhibited 
the rate of uptake.23 The pharmacokinetics of gadoxetic acid 
is characterized by a capacity-limited transport process via 
the biliary route of elimination, thus strongly resembling 
the pharmacokinetics of some biliary x-ray contrast media 
(iotroxic, iodipamic, or idoxamic acid) or the synthetic dyes 
(indocyanine green).24 Michaelis–Menten kinetics in the 
extrarenal elimination was considered as the rate-limiting 
process of gadoxetic acid, the binding to plasma protein 
of which is small (10.3 ± 1.4%). Biliary elimination was 
significantly inhibited by the intravenous (IV) coadminis-
tration of sulfobromophthalein, whereas tauroglycocholate 
revealed no effect, indicating the involvement of the so-
called organic anion plasma membrane transport system 
for the hepatic uptake. The transport of gadoxetic acid 
from the cytoplasm to the bile is mainly determined by the 
capacity of the transport protein glutathione-S-transferase, 
as demonstrated by in vitro binding studies. A hepatobiliary 
transport maximum of 9.2 µmol/min⋅kg was evaluated by 
infusion studies. No metabolites were detected either in 
the bile or in the urine, and enterohepatic circulation can 
be excluded.25,26
Pharmacology of gadoxetic acid
Gadolinium-ethoxybenzyl-diethylenetriamine-pentaacetic-
acid (Gd-EOB-DTPA, SH L 569 B®; gadoxetic acid disodium, 
Primovist® outside the United States or Eovist® in the United 
States) is a paramagnetic hepatobiliary contrast agent with 
hepatocellular uptake via the anionic-transporter protein 
and a molecular weight of 725.71 Da (C23H28GdN3Na2O11).18 
The compound was extensively tested preclinically in 
various species.24–35 Gadoxetic acid exhibits a T1-relaxivity 
of 4.9 mM−1⋅s−1 at 0.47 T in water, comparable to that of 
gadopentetate dimeglumine 3.7 mM−1⋅s−1, but shows a 
higher T1-relaxivity (R1 8.2 mM−1⋅s−1) in human plasma 
than gadopentetate dimeglumine (R1 5.0 mM−1⋅s−1). This 
may be explained by the greater degree in protein binding 
(10.7% ± 3.4%) compared with gadopentetate dimeglumine 
(1.6% ± 4.2%). At 37°C, the solution has an osmolality of 
0.89 osmol/kg H2O and a viscosity of 1.22 mPas.   Gadoxetic Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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acid is an aqueous formulation with a   concentration 
of 0.25 mol/L and a thermodynamic stability constant 
of 10.20 Biodistribution studies in dogs using radioactive153 
Gd-labeled Gd-EOB-DTPA revealed a dose-dependent renal 
(40.9% ± 2.35%) and biliary (57.0% ± 2.49%) excretion with-
out signs for metabolism and an enterohepatic recirculation 
of approximately 2.1% ± 0.56%.24–26,35
Gadoxetic acid was well tolerated within phase 1 trials at 
doses of 10, 25, 50, and 100 µmol Gd/kg, with no important 
side effects or changes in laboratory parameters.27 Results 
of laboratory tests, clinical measurements, and pharma-
cokinetic data were obtained in 44 healthy volunteers in 
a double-blinded, randomized, placebo-controlled design. 
MR images were obtained in another 16 healthy volunteers 
before and after 6 hours of fast IV administration of gadoxetic 
acid. Homogeneous enhancement of liver parenchyma was 
observed immediately after injection of the contrast agent. 
Peak liver signal intensity (SI) was noted 20 minutes after 
injection, followed by plateau-like enhancement over about 
2 hours. The common bile duct was hyperintense within 
10 minutes after injection in all volunteers. The time course 
of contrast enhancement in bile ducts and the gallbladder 
showed intense signal enhancement beginning 5–16 minutes 
after injection (mean, 10 minutes) and persisting for as long 
as 360 minutes. The duration of signal enhancement was 
significantly longer for higher doses (50, 100 µmol/kg) than 
for lower doses (10, 25 µmol/kg). Intrahepatic bile ducts were 
hyperintense when compared with liver parenchyma in all 
subjects receiving 10 µmol/kg contrast agent from approxi-
mately 50–120 min after its application. Intrahepatic bile 
ducts were not displayed using the higher doses,   probably 
because of the strong enhancement of the liver parenchyma. 
Gallbladder contrasting was achieved in all cases begin-
ning 7–33 minutes after injection (mean, 19 minutes) and 
remained visible for up to 360 minutes in 94% of cases. 
Hyperintense visualization of normal extrahepatic bile ducts 
as well as the gallbladder was regularly achieved.36
During 2 subsequent clinical phase 2 trials, the diagnostic 
efficacy and safety of gadoxetic acid were explored at 5 doses 
(3.0; 6.0; 12.5, 25, and 50 µmol gadoxetic acid/kg body 
weight [bw]) when compared with placebo (0.9% saline) in 
patients with known focal liver lesions. These 2 clinical phase 
2 trials revealed a lowest effective dose of 25 µmol gadoxetic 
acid/kg bw.37 The number of patients with more lesions being 
visualized on postcontrast than on precontrast scans increased 
with increasing dose up to 12.5 µmol gadoxetic acid/kg bw. 
The enhancement of hepatic vessels and liver parenchyma 
during dynamic imaging following bolus injection at 2 mL/s 
also increased with increasing dose. There was no significant 
improvement in quantitative or qualitative efficacy param-
eters at 45 minutes after injection compared with 20 minutes 
after injection. Dynamic imaging can start immediately after 
bolus injection, and accumulation phase imaging can be 
performed at 20 minutes after injection.37–40
The subsequent European phase 3 multicenter trial 
was performed with a dose of 25 µmol gadoxetic 
acid/kg bw (BW).41,42 The safety and efficacy of gadoxetic 
acid   disodium-enhanced MRI for the detection of focal liver 
lesions were investigated with a study design correlating 
MRI with the results of histopathologic examination and/or 
intraoperative ultrasonography used as a standard of refer-
ence. In the off-site evaluation, 2 of the 3 blinded readers 
showed a statistically significant difference in lesion detec-
tion between precontrast and postcontrast MRI. A large num-
ber of additionally correctly detected and localized lesions 
were smaller than 1 cm. No clinically relevant changes in 
hemodynamic or laboratory parameters were observed. No 
death or any adverse event (AE) leading to discontinuation 
of the study was reported. The most frequently reported 
symptoms of definitely or probably related AEs were nausea, 
vasodilatation, headache, taste perversion, and pain at the 
injection site.42
Efficacy
A second phase 3 multicenter trial was performed in the 
United States between September 1998 and April 2000 to 
assess the efficacy and safety of postcontrast MRI with gad-
oxetic acid compared with that of precontrast MRI in patients 
who were known to have or suspected to have liver lesions and 
who were scheduled for hepatic surgery. A total of 172 patients 
were enrolled. After precontrast MRI, 169 patients (94 men, 
75 women) received an IV bolus injection of 25 µmol/kg 
gadoxetic acid and underwent dynamic and delayed MRI 
20 minutes after the injection. The standard of reference 
was surgery with intraoperative ultrasonography, biopsy, 
and pathologic evaluation of resected liver segments and/
or 3-month follow-up of nonresected segments. Using MRI, 
316 lesions were identified in 131 patients. In 77%, 72%, and 
71% of patients for readers 1, 2, and 3, respectively, more 
lesions were observed using combined precontrast and post 
contrast MRI than using precontrast MRI alone.   Compared 
with precontrast MRI, postcontrast MRI with gadoxetic acid 
demonstrated improved sensitivity for lesion detection in most 
of the blinded readers, with no substantial AEs.   Sensitivity 
values for blinded readings were significantly greater at post-
contrast MRI than at precontrast MRI.43Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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More recently, Hammerstingl et al41 published a multi-
member study on the diagnostic efficacy of CE-MRI with 
gadoxetic acid as opposed to contrast-enhanced CT in the 
diagnosis of focal liver lesions. A total of 169 patients with 
lesions were enrolled, and they underwent CE-MRI with 
gadoxetic acid and CT within 6 weeks. The standard of 
reference was established by evaluating the liver specimens 
of 131 patients with 302 focal lesions using intraoperative 
ultrasonography. The strength of detecting small focal lesions 
using CE-MRI with gadoxetic acid is shown by the highest 
rate of correctly detected lesions with a diameter below 
1 cm. Differential diagnosis was also superior for CE-MRI 
with gadoxetic acid (82.1%) vs CT (71.0%). Subsequently, a 
change in surgical therapy was achieved in 14.5% of patients. 
Therefore, CE-MRI with gadoxetic acid was superior in the 
diagnosis and therapeutic management of focal liver lesions 
compared with CT.
Safety
Gadoxetic acid is currently an US Food and Drug Admin-
istration (FDA) category C drug – the effect of which 
upon a newborn is unknown. When using gadoxetic acid, 
the usual safety precautions for MRI must be observed, 
for example, exclusion of cardiac pacemakers and fer-
romagnetic implants. The patient should refrain from 
eating for 2 hours prior to examination to reduce the risk 
of aspiration, as nausea and vomiting are known possible 
adverse reactions. The contrast agent should be admin-
istered with the patient lying down. After the injection, 
the patient should be kept under observation for at least 
30 minutes, because most of the undesirable effects are 
found to occur within this time. This medicinal product 
contains 11.7 mg sodium/mL, and the dosage is 0.1 mL/
kg bw. This may be taken into consideration by patients 
on a controlled sodium diet.
There have been reports on nephrogenic systemic fibrosis 
(NSF) associated with the use of some gadolinium-containing 
contrast agents in patients with acute or chronic renal impair-
ment (glomerular filtration rate , 30 mL/min/1.73 m2), acute 
renal insufficiency of any severity due to the   hepatorenal 
syndrome, or in the perioperative liver transplantation period. 
As there is a possibility that NSF may occur with the use of 
Primovist, it should, therefore, only be used in these patients 
after careful risk/benefit assessment, if the diagnostic infor-
mation is essential and not available with non-CE-MRI. 
All patients should be screened, in particular, patients older 
than 65 years, for renal dysfunction by obtaining a history 
of laboratory tests.
There is no evidence to support the initiation of hemo-
dialysis for the prevention or treatment of NSF in patients 
not already undergoing hemodialysis. Caution should be 
exercised in patients with severe renal impairment due to the 
reduced elimination capacity of gadoxetic acid.
Care should be taken when gadoxetic acid is administered 
to patients with severe cardiovascular problems because only 
limited data are available so far. The contrast agent should 
not be used in patients with uncorrected hypokalemia. Special 
care should be taken in the following patient groups: patients 
with (1) known congenital long QT syndrome or a familial 
history of congenital long QT syndrome; (2) known previous 
arrhythmias who are currently taking class III antiarrhyth-
mic drugs, such as amiodarone and sotalol, which prolong 
cardiac repolarization. Gadoxetic acid may cause transient 
QT prolongation in individual patients.
Allergy-like reactions, including shock, are known to be 
rare events after the administration of gadolinium-based MRI 
contrast media. Most of these reactions occur within half an 
hour after the administration of contrast media. However, 
as with other contrast media of this class, delayed reactions 
may occur after hours to days in rare cases. Medication for 
the treatment of hypersensitivity reactions and preparedness 
for the institution of emergency measures are necessary. The 
risk of hypersensitivity reactions is higher in case of previous 
reaction to contrast media or history of bronchial asthma or 
allergic disorders.
Hypersensitivity reactions can be more intense in patients 
on β-blockers, particularly in the presence of bronchial 
asthma. It is considered that patients on β-blockers might be 
refractory to standard treatment of hypersensitivity reactions 
with β-agonists. If hypersensitivity reactions occur, injection 
of the contrast medium must be discontinued immediately.
Intramuscular administration may cause local intolerance 
reactions, including focal necrosis and should therefore be 
strictly avoided. No interaction studies have been performed 
in humans. However, in general, anionic drugs primarily 
excreted into the bile, such as rifampicin, may interfere in 
the hepatic contrast enhancement and the biliary excretion of 
gadoxetic acid. Animal studies demonstrated that compounds 
belonging to the class of rifamycins block the hepatic uptake 
of gadoxetic acid, thus reducing the hepatic contrast effect. 
In this case, the expected benefit of an injection of gadoxetic 
acid might be limited. No further interactions with other 
medicinal products are known. Elevated levels of bilirubin 
or ferritin can reduce the hepatic contrast effect of gadoxetic 
acid. Serum iron determination using complexometric meth-
ods (eg, ferrocine complexation method) may result in false Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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values for up to 24 hours after the examination with gadoxetic 
acid because of the free complexing agent contained in the 
contrast medium solution.44,45
In a more recent trial analyzing the efficacy and safety 
of gadoxetic acid in Chinese patients, no serious AEs 
were observed in 234 patients (79 female, 155 male; age, 
50.2 years). Other AEs were reported in 20 of 234 patients, 
including nausea (2 patients), pain at the injection site (1), 
increased systolic/diastolic blood pressure (2), increased 
blood glucose (2), decreased white blood cell count (2), 
increased blood bilirubin (3), increased blood phosphorus 
(1), increased alanine aminotransferase (1), increased 
aspartate aminotransferase (1), hypertension (4), and 
hypotension (2).46
Effect of hepatic and renal 
impairment
The impact of hepatic and/or renal impairment was inves-
tigated in a special population study. Groups of volunteers 
with various levels of impaired hepatic or renal function, 
coexisting hepatic and renal impairment, and a control were 
enrolled. Pharmacokinetic parameters of gadoxetic acid 
derived from the serum level data were markedly altered 
only in end-stage renal failure. Mild to severe hepatic 
impairment and moderate renal impairment did not markedly 
change the pharmacokinetic parameter values. Considering 
the safety profile, the observed differences in the patients 
with end-stage renal failure may not be clinically relevant. 
Hepatic parenchymal enhancement with a standard dose of 
gadoxetic acid was accomplished in all patient groups. For 
clinical use, the enhancement was sufficient above 50%, and 
of sufficient duration with 60 minutes or more. No special 
considerations appear to be required in the presence of end 
organ disease. Gadoxetic acid, as a single rapid IV dose of 
25 µmol/kg bw, was safe and well tolerated by all patients 
in this study. This included patients who had hepatic or renal 
impairment (including end-stage renal disease), patients with 
both hepatic and renal impairment, and healthy male and 
female volunteers (younger and older than 65 years) with 
normal liver and kidney function.47
Patients
Gadoxetic acid is generally well tolerated by patients in 
  clinical trials and clinical practice as observed in a most 
recent trial.46 Most undesirable effects were transient and 
of mild to moderate intensity. The most commonly noted 
AEs were nausea and headache with an incidence of 1.1%. 
Coldness, warmth, or pain at the injection site, injection 
site reaction, and accumulation of fluid at the injection site 
were rare. The clinical usefulness and accuracy have already 
been covered beyond reports on clinical trials. Zech et al48,49 
presented an economic evaluation comparing gadoxetic acid 
with extracellular contrast-media-enhanced MRI (ECCM-
MRI) and 3-phase multidetector computed tomography 
(MDCT) in the development of patients with metachro-
nous colorectal liver metastases. MRI with gadoxetic acid 
  potentially leads to cost savings by improving preoperative 
planning and decreasing intraoperative changes.42
Clinical applications
Liver
Liver imaging with gadoxetic acid typically consists of the 
acquisition of precontrast T1- and T2-weighted images fol-
lowed by bolus injection and dynamic T1-weighted imaging 
of the perfusion phase. Since the injected dose is just one 
quarter of the regular gadolinium dose, contrast enhance-
ment is weaker than that experienced with nonspecific gado-
linium chelates.50 Nevertheless, the perfusion phase allows 
for some assessment of perfusion patterns of liver lesions. 
Accumulation-phase images may be obtained upon washout 
of unspecifically perfused liver lesions and may start as early 
as 8 minutes after injection as tested in phase 3 trials.42 Acquir-
ing T2-weighted images following perfusion-phase imaging 
shortens the examination time with reproducible image 
quality.51 Gadoxetic acid improves the detection of a spectrum 
of liver lesions, especially smaller lesions. These results apply 
mainly to the accumulation-phase images, while perfusion-
phase images are more utilized for lesion characterization. For 
characterization, the per-patient sensitivity was significantly 
higher on postcontrast images alone or on combined images 
compared with the precontrast MR images.42
Metastases
Tumors not derived from hepatocytes, such as liver metasta-
ses or cholangiocarcinoma do not take up the gadoxetic acid 
in the accumulation phase, thereby increasing the postcon-
trast tumor conspicuity. During the perfusion phase, liver 
metastases show the highest enhancement of 90–120 seconds 
following IV injection of gadoxetic acid. Tumor enhancement 
then gradually decreases and stabilizes after 10 minutes. Liver 
enhancement is stronger than the enhancement of metastases 
after 3 minutes following IV injection of gadoxetic acid. 
Therefore, lesion–liver contrast of liver metastases gradually 
increases from 2 minutes postcontrast to 10 minutes postcon-
trast. The increase from precontrast and early postcontrast 
(2 minutes) SIs to later postcontrast SIs ($10 minutes) is Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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significant; however, differences among later postcontrast 
time points (10, 20, and 45 minutes) are not significant.52 
Gadoxetic acid provides improved detection and charac-
terization of liver metastases compared with unenhanced 
and Gd-enhanced MRI, both experimentally and clinically. 
Almost no metastasis showed complete enhancement during 
dynamic imaging as investigated during the US phase 3 trial. 
Moreover, in some cases, there is partial, often rim enhance-
ment in metastases, which do not possess a uniform and 
homogeneously distributed vasculature. In the accumulation 
phase, most metastases do not enhance (Figure 1).42
Hepatocellular carcinoma
Depending on the tumor vascularity, some tumors may 
enhance stronger and some may enhance weaker than nor-
mal liver parenchyma as also known for gadolinium chelates 
(Figures 3 and 4).53,54 Gadoxetic acid has the potential capac-
ity for the concurrent assessment of vascularity of HCC 
and hepatocellular-specific properties within the tumor.55 
Persisting enhancement during the accumulation phase has 
been subject to experimental and clinical reports.56 Fujita 
et al57 described potential enhancement of moderately dif-
ferentiated HCCs in a mice model. In the US phase 3 trial, 
HCCs were usually described as enhancing heterogeneously 
in the dynamic phase. Enhancement was greater during the 
dynamic phases than during the hepatocyte phase.43 In a sub-
group analysis within the European phase 3 trial, 40 patients 
with histopathologically proven HCC were selected. No 
difference was found between combined pre- or postcontrast 
MRI and spiral CT for lesion classification.58 Considering 
typical enhancement patterns, gadoxetic acid-enhanced 
MRI during the accumulation phase helps discriminating 
HCC from arterial-enhancing pseudolesions during the 
arterial phase. In a recent study by Sun et al,59 42 of 44 
HCCs demonstrated low SI and only 2 showed iso or high 
SI on the hepatobiliary phase of gadoxetic acid-enhanced 
MRI. Alternatively, 50 of 53 arterial-enhancing pseudole-
sions showed iso SI on the hepatobiliary phase, and only 
2 showed low SI.
Narita et al60 investigated the uptake of gadoxetic acid in 
the hepatobiliary phase in HCC. Enhancement ratios (ERs) 
and expression levels of the organic anion transporter (OATP) 
1B3 protein were examined. Gadoxetic acid accumulated in 
the hepatobiliary phase in 6 of the 22 cases. All 6 gadoxetic 
acid-positive cases were moderately differentiated HCC, 
but 11 other moderately differentiated HCCs did not show 
gadoxetic acid uptake. Histopathologically, 4 gadoxetic acid-
positive HCCs and 5 gadoxetic acid-negative HCCs produced 
bile. HCCs with gadoxetic acid uptake overexpressed 
OATP1B3 compared with HCCs without gadoxetic acid 
uptake, and OATP1B3 levels were significantly correlated 
with ERs (r = 0.91, P , 0.0001). The study elegantly revealed 
that uptake of gadoxetic acid in HCC is determined by the 
expression of OATP1B3 rather than by tumor differentiation 
or bile production. This potential problem is underestimated 
in most studies.61,62
Hemangioma
Enhancement of liver hemangioma is typically visible during 
the perfusion phase up to 10 minutes following IV injection 
of gadoxetic acid.40,63 In the US phase 3 trials, an increasing 
proportion of hemangiomas displayed partial enhancement 
as time elapsed in the dynamic phase. In the accumulation 
phase, most of the hemangiomas did not enhance, or only 
partially enhanced.43 Delayed images obtained at 45 min-
utes showed no significant difference of hemangiomas 
compared with metastases or HCCs. Hemangiomas initially 
demonstrated a slight decrease in lesion-liver contrast due 
to the relative tumor enhancement following IV injection 
of gadoxetic acid. The increase from precontrast to early 
postcontrast values up to 10 minutes was not significant, 
and lesion–liver contrast still increased between 20 and 
45 minutes (P # 0.05).52 Liver hemangiomas are more 
conspicuous on turbo spin echo (TSE)-T2 images than on 
gradient echo (GRE)-T1 or short-tau inversion recovery 
(STIR) images following gadoxetic acid administration, 
and the conspicuity on TSE-T2 images is not affected by 
the contrast agent.64
FNH and adenoma
Hepatocyte-derived benign liver tumors exhibit pro-
longed tumor enhancement due to specific intracellular 
uptake of gadoxetic acid (Figure 2). Most of FNH lesions 
enhance completely during dynamic-phase imaging and 
  accumulation-phase imaging, most FNH show either 
complete or partial enhancement.43 Zech et al65 looked at 
the diagnostic performance of MRI with gadoxetic acid in 
comparison with precontrast MRI and CT in the specific 
diagnosis FNH. Characterization and enhancement patterns 
were evaluated in 59 confirmed FNH lesions. Complete 
or partial enhancement was present in the early dynamic 
phase in most lesions (80%–90%) and was mainly homog-
enous. Enhancement in the hepatocyte phase after 10 and 
20 minutes was observed in up to 90% of lesions. FNH 
lesions show similar enhancement characteristics to those 
of extracellular contrast agents in the early dynamic phase Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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after bolus injection. During the hepatocyte phase, after 
20 minutes, enhancement is regularly seen.66
Adenomas display considerable variability in enhance-
ment, during both dynamic-phase and accumulation-phase 
imaging. Some lesions show homogeneous enhancement to 
the same degree as, or even more than, the surrounding paren-
chyma. The lack of a T2-weighted hyperintense central scar is 
important to avoid a misdiagnosis of FNH. Some adenomas 
show only minimal uptake, which does not allow reliable 
differentiation between adenoma and well-differentiated 
HCC so far. In one series of images, intracellular uptake 
of gadoxetic acid in adenomas was found to be absent or 
strongly reduced during the hepatocyte phase. Therefore, 
the differentiation of adenomas from dysplastic or malignant 
lesions is not possible.49,53,63,67
Biliary system
Imaging of biliary excretion and hepatic function with gadox-
etic acid-enhanced MRI has been investigated experimentally 
in normal and diseased liver.68–71 Due to the strong biliary 
excretion of gadoxetic acid in humans, the enhancement of the 
biliary system and drainage into the duodenum are visualized 
within several minutes after administration in patients without 
biliary obstruction.72 Analysis of the course of enhancement 
in bile ducts and the gallbladder revealed that the common 
bile duct showed dose-dependent intense signal enhancement 
beginning at less than 5 minutes after injection and persisting 
for more than 2 hours. Intrahepatic bile ducts are hyperintense 
when compared with liver parenchyma. The gallbladder shows 
signal enhancement typically beginning at .7 minutes after 
injection and remains visible for up to 6 hours in most sub-
jects.36 Residual hepatic enhancement during the accumulation 
phase does interfere with biliary visualization.73,74 The added 
value of gadoxetic acid-enhanced magnetic resonance cho-
langiography (MRC) to unenhanced magnetic resonance 
cholangiopancreatography (MRCP) is considered modest, and 
the indication should be limited to selected cases.73,74
Comparative imaging studies
There are several comparative studies available, which may 
show the value of gadoxetic acid from a more practical perspec-
tive. A randomized study comparing liver   enhancement with 
gadoxetic acid and gadobenate   dimeglumine in 295 patients 
demonstrated that liver enhancement in the accumulation 
phase after the injection of gadoxetic acid was superior to that 
of gadobenate dimeglumine.75
Hammerstingl et al41 published a multicentric trial compar-
ing MRI with gadoxetic acid and CT in the diagnosis of focal 
liver lesions with a standard of reference of 169 patients with 
hepatic lesions eligible for surgery. In the blinded reading, 
there was a trend toward gadoxetic acid-enhanced MRI, not 
reaching statistical significance. The highest rate of correctly 
detected lesions with a diameter below 1 cm was achieved 
by gadoxetic acid-enhanced MRI. Differential diagnosis was 
superior for gadoxetic acid-enhanced MRI with 82.1% vs CT 
with 71.0%. A change in surgical therapy was documented 
in 19 of 131 patients (14.5%) who underwent postgadoxetic 
acid-enhanced MRI. Gadoxetic acid-enhanced MRI was con-
sidered superior in the diagnosis and therapeutic management 
of focal liver lesions compared with CT.42
Ichikawa et al76 studied and compared gadoxetic acid-
enhanced MRI with unenhanced MRI and triphasic CT for 
the detection and characterization of focal liver lesions in 
178 patients with suspected focal hepatic lesions enrolled in a 
multimember trial. Gadoxetic acid-enhanced MRI improved 
the detection and characterization of focal hepatic lesions 
compared with unenhanced MRI. Combined MRI showed 
higher sensitivity in lesion detection than CT, with the results 
being statistically significant for on-site readers and 2 of 3 
blinded readers. Higher sensitivity in lesion detection using 
combined MRI compared with CT was also clearly demon-
strated in the following subgroups: (1) patients with lesions 
with a diameter #20 mm; (2) patients with cirrhosis; and 
(3) patients with HCC.
Kim et al62 compared the diagnostic performance of gad-
oxetic acid-enhanced MRI at 3 Tesla with that of triple-phase 
16-, 40-, and 64-MDCT in the preoperative detection of HCC 
in 62 consecutive patients. The diagnosis of HCC was estab-
lished after surgical resection. For each observer, the areas 
under the receiver operating characteristic (ROC) curve were 
0.971, 0.959, and 0.967 for MRI and 0.947, 0.950, and 0.943 
for CT. The sensitivity differences in positive and negative 
predictive values between the 2 techniques for each observer 
were not statistically significant (P . 0.05). Gadoxetic acid-
enhanced MRI and triple-phase MDCT had similar diagnostic 
performance in the preoperative detection of HCC, but MRI 
may be better than MDCT in the detection of HCC with a 
diameter #1 cm or according to a subgroup analysis.
Kim et al77 compared the diagnostic performance of gad-
oxetic acid-enhanced MRI with ferucarbotran-enhanced MRI 
for the detection of liver metastases in 36 of 80 patients with 
liver metastases. There was a trend toward increased areas 
under the ROC curve for the gadoxetic acid set (0.950 and 
0.948) as compared with the ferucarbotran set (0.941 and 
0.939) of images, but no significant difference was found 
for both observers. Sensitivities of the gadoxetic acid set Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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(93.8% and 92.5%) were also slightly better than those of the 
ferucarbotran set (88.8% and 87.5%) with no significant dif-
ference (P = 0.13). The 2 image sets showed similar positive 
predictive values (98.7% and 98.6%, respectively). Gadoxetic 
acid-enhanced MRI showed comparable diagnostic perfor-
mance to ferucarbotran-enhanced MRI for the detection of 
liver metastases.
Summary
Gadoxetic acid, as a bolus injectable paramagnetic hepa-
tobiliary contrast agent combines features of extracellular 
agents, such as initial tumor perfusion and enhancement 
on delayed images of tumors with a large blood pool or 
with hepatocytes maintaining cell membrane function. The 
detection and characterization of focal liver disease are 
significantly improved compared with unenhanced MRI, 
MRI with unspecific contrast agents, and CT.78 Innovative 
rapid acquisition techniques with near isotropic 3D pulse 
sequences with fat saturation parallel the technical progress 
made by MDCT combined with an impressive improvement 
in tumor–liver contrast.
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